ライフサイエンスコーパス: immunoconjugate

1 opic tumors selectively using an activatable immunoconjugate.

2 in >95% of the (64)Cu being chelated by the immunoconjugate.

3 cells and complement in the presence of the immunoconjugates.

4 ) to the activity of bivalent IgG-containing immunoconjugates.

5 und to the radiometal to create radiolabeled immunoconjugates.

6 ell death induced by the fusion peptides and immunoconjugates.

7 cted tumor, which synthesize and secrete the immunoconjugates.

8 competitive binding assay demonstrates that immunoconjugate 2 binds to SKOV3 tumor cells comparably

9 thiol-maleimide chemistry, thereby yielding immunoconjugate 2.

10 Using fluorescence microendoscopy to monitor immunoconjugate activation and micrometastatic disease,

11 The results demonstrate that a mutated fVII immunoconjugate, administered separately or together wit

12 For the next generation of immunoconjugates, advances in protein engineering will p

13 The in vitro results suggest that the immunoconjugates also could activate a specific cytolyti

14 icited by active immunization with a cocaine immunoconjugate and binds free cocaine with excellent sp

15 lanoma protein was immunoprecipitated by the immunoconjugates and analyzed by mass spectrometry, usin

16 o acid produces a chemical "handle" by which immunoconjugates and multimers can be engineered.

17 Immunoconjugates and multispecific antibodies are rapidl

18 ells were conducted with the photosensitizer immunoconjugates and, for comparison, with free PPa.

19 rosine kinase inhibitors, ligand conjugates, immunoconjugates, and antisense oligonucleotides.

20 sine kinase inhibitors, synthetic retinoids, immunoconjugates, and immunosuppressive molecules with n

21 geted therapies using monoclonal antibodies, immunoconjugates, and immunotoxins.

22 icant barriers to penetration by antibodies, immunoconjugates, and other immunotoxins.

23 the development of a mouse B cell-depleting immunoconjugate (anti-CD22 monoclonal antibody [mAb] con

24 SMA(ext), thus targeting viable tumor, these immunoconjugates are better candidates for targeted radi

25 Our studies demonstrated that these immunoconjugates are effective both in vitro and in test

26 The resulting boron-rich immunoconjugates are formed efficiently, are readily pur

27 However, these immunoconjugates are highly prone to noncovalent, dimeri

28 ability, minimizing the toxicity of 90Y-DOTA immunoconjugates arising from loss of 90Y to bone.

29 receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2).

30 In summary, immunoconjugates based on lytic peptides are a promising

31 Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is i

32 er immunoconjugate, provided photosensitizer immunoconjugate binding was saturated.

33 The Fc effector domain of the immunoconjugates binds natural killer (NK) cells and als

34 ature, presumably mediated by the factor VII immunoconjugate bound to tissue factor on neovasculature

35 n chemotherapy strategies, radiotherapy, the immunoconjugate brentuximab, checkpoint inhibitors nivol

36 The immunoconjugate C242-DM1 was prepared by conjugating DM1

37 ggest that ephB2 is an attractive target for immunoconjugate cancer therapy.

38 4 days after treatment with a single dose of immunoconjugate carrying 2.5 ng of Dox, LoVo and SW-480

39 refractory CD33(+) AML were treated with an immunoconjugate (CMA-676) consisting of humanized anti-C

40 Immunoconjugates composed of antibodies conjugated to ra

41 tion-incompetent adenoviral vectors encoding immunoconjugates composed of the Fc region of an IgG1 im

42 The synthesis of the immunoconjugate consists of covalent attachment of the N

43 One immunoconjugate containing an antibody and a chemotherap

44 Two antimelanoma immunoconjugates containing a human single-chain Fv (scF

45 a crenulata (KLH) were prepared as effective immunoconjugates containing a sensitive fluorescent repo

46 othelial cells and tumor cells, a factor VII immunoconjugate could be used for immunotherapy against

47 tive vaccination of mature rats with ghrelin immunoconjugates decreases feed efficiency, relative adi

48 Herein, we generated a bispecific immunoconjugate [denoted as Bs-F(ab)2] by linking two an

49 itro cytolysis assay was used to test for an immunoconjugate-dependent specific cytolytic response ag

50 MLN2704 is an immunoconjugate designed to deliver the maytansinoid ant

51 N,N',N",N"'-tetraacetic acid) and the intact immunoconjugate DOTA-NR-LU-10 were labeled to high speci

52 experiments with 2IT-BAD-Lym-1 and a second immunoconjugate, DOTA-peptide-chimeric L6, with 248-492

53 that intratumoral delivery of the factor VII immunoconjugate, either alone or together with the singl

54 Phase I trials of a calicheamicin immunoconjugate for treatment of acute myeloid leukemia

55 of acute myeloid leukemia and a doxorubicin immunoconjugate for treatment of carcinoma have recently

56 men described here could be applied to other immunoconjugates for targeted therapy of a broad spectru

57 of targeted amphipathic fusion peptides and immunoconjugates for the ablation of prostate cancer cel

58 per L) could receive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intrave

59 Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resista

60 unization with the second-generation cocaine immunoconjugate GND-keyhole limpet hemocyanin (KLH) or w

61 The IC(50)s of the immunoconjugate H-GA were 10-200-fold lower than that of

62 Unlabeled immunoconjugates had no effect on tumor growth.

63 Our results show that (1) the immunoconjugate has B-cell-specific in vitro and in vivo

64 This novel immunoconjugate has shown cytotoxic anti-prostate cancer

65 Radioimmunotherapy (RIT) with 90Y-labeled immunoconjugates has shown promise in clinical trials.

66 Several immunoconjugates have demonstrated impressive antigen-sp

67 reviously that an interferon (IFN)-MAb (1:1) immunoconjugate (IC) enhances tumor uptake by a factor o

68 A pretreatment with a single dose of an immunoconjugate (IC) that promises to enhance tumor upta

69 ules and anti-LFA-1-Ricin and anti-Iak-Ricin immunoconjugates (IC) were prepared and administered in

70 The efficacy and safety of an immunoconjugate (icon) molecule, composed of a mutated m

71 Immunoconjugates (ICs) consist of a cytotoxic effector c

72 ls and can be used as a target for cytotoxic immunoconjugates (ICs), in which cell-killing moieties,

73 t further broad clinical development of this immunoconjugate in CanAg-expressing tumors.

74 ng the rationale for clinical trials of this immunoconjugate in MM.

75 The bloodborne immunoconjugates induce a cytolytic immune response agai

76 Lym-1-21T-BAD immunoconjugate intermediate was prepared according to o

77 The immunoconjugate is composed of self-quenching, near-infr

78 in pediatric patients also suggest that the immunoconjugate is reasonably well tolerated.

79 Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myel

80 nical studies using the (111)In radiolabeled immunoconjugate, MAb 7E11-C5.3-GYK-DTPA (capromab pendet

81 erapy with a HER50 and HER66 photosensitizer immunoconjugate mixture was significantly more effective

82 The immunoconjugate molecule (Icon), which binds with high a

83 e treatment involves systemic delivery of an immunoconjugate molecule composed of a tumor-targeting d

84 Immunoconjugates--monoclonal antibodies (mAbs) coupled t

85 Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD33 antibody linked to calic

86 Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 antibody that facilitate

87 describe the preclinical profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22

88 tuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl

89 N901-bR is an immunoconjugate of N901 antibody with blocked ricin (bR)

90 Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuz

91 Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum

92 ab-PEG24-EGF at the NOAEL, or with unlabeled immunoconjugates or normal saline.

93 ype-specific anti-Ia mAb, haplotype-specific immunoconjugates, or mAb directed against graft APC, adh

94 r-killing power of toxic effector molecules, immunoconjugates permit sensitive discrimination between

95 vent spurs antibody production against these immunoconjugates, possibly leading to drug sequestration

96 Preclinical studies using immunoconjugates prepared with toxins, drugs, or other a

97 The immunoconjugate preserved both antibody specificity and

98 Splenocytes from immunoconjugate pretreated donors inhibited the mixed ly

99 However, reported 90Y-DOTA immunoconjugate product yields have been typically only

100 The immunoconjugate product, 2IT-BAD-Lym-1, was labeled in e

101 as been eliminated or greatly reduced in the immunoconjugate products.

102 The specificity of antibodies have made immunoconjugates promising vectors for the delivery of r

103 rapy with a single anti-HER2 photosensitizer immunoconjugate, provided photosensitizer immunoconjugat

104 e of radiation-induced damage of 90Y-labeled immunoconjugate radiopharmaceuticals during preparation

105 ies (ENb) and imageable and proapoptotic ENb immunoconjugates released from stem cells (SC) to ultima

106 Several challenges in optimizing immunoconjugates remain, however, including poor intratu

107 otic/necrotic death in cells, treatment with immunoconjugates resulted in apoptotic death.

108 cination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for th

109 r alone or together with the single-chain Fv immunoconjugate, resulted in growth inhibition and regre

110 g properties and rapid systemic clearance of immunoconjugates should lead to the design of effective

111 The purified immunoconjugates showed similar binding specificity as d

112 mediated effector mechanisms or as cytotoxic immunoconjugates, such as immunotoxins (ITs).

113 BR96 immunoconjugates synthesized from methoxytriethylene gly

114 These results show that an immunoconjugate targeted to CD33 can selectively ablate

115 eparately or together with a single-chain Fv immunoconjugate that binds to the tumor cells, can inhib

116 CD19 for immunotoxins and probably for other immunoconjugates that act inside cells.

117 We have synthesized immunoconjugates that induce an effective immune respons

118 C242-DM1 represents a new generation of immunoconjugates that may yet fulfill the promise of eff

119 Gemtuzumab ozogamicin (GO) is a novel immunoconjugate therapy for acute myeloid leukemia (AML)

120 Tat (GRKKRRQRRRPPQGYG) was also added to the immunoconjugate to aid nuclear translocation.

121 Because the binding of a fVII immunoconjugate to TF might cause disseminated intravasc

122 oved yields are needed for RIT with 90Y-DOTA immunoconjugates to be practical.

123 eloped fluorophore- and radioisotope-labeled immunoconjugates to target a DDR signaling protein, phos

124 se is the delivery of enough photosensitizer immunoconjugates to target cells.

125 tope HER2 targeting to boost photosensitizer immunoconjugate uptake as a way of enhancing photoimmuno

126 emtuzumab ozogamicin (GO; Mylotarg), a novel immunoconjugate used for treatment of acute myeloid leuk

127 At equimolar concentrations, the immunoconjugate was 8 times more cytotoxic against two c

128 cell adhesion molecule (EpCAM) targeting MMC-immunoconjugate was prepared and dual-labeled with (64)C

129 The immunoreactivity of 90Y-labeled immunoconjugates was 100%+/-11%.

130 To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified

131 The tumor-effective half-lives of the immunoconjugates were 39 hr for indium and 46 hr for ytt

132 Indium-111-IgM and 90Y-IgM immunoconjugates were compared in nude mice at 2, 24, 72

133 Anti-HER2 photosensitizer immunoconjugates were constructed from two monoclonal an

134 ulfanyl(alkanoyl) groups for taxoid-antibody immunoconjugates were designed, synthesized and their ac

135 The immunoconjugates were encoded as secreted molecules in a

136 Photosensitizer immunoconjugates were labeled instead with a promising a

137 On a per mole basis, photosensitizer immunoconjugates were less phototoxic than free PPa, but

138 hototoxic than free PPa, but photosensitizer immunoconjugates were selective for target cells whereas

139 High mole ratio BR96 immunoconjugates were synthesized using branched peptide

140 Photosensitizer immunoconjugates with PPa/mAb molar ratios up to approxi

141 riginally developed to label photosensitizer immunoconjugates with the photosensitizer, benzoporphyri